Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 1

2(33.3%)

Phase 4

2(33.3%)

6Total

Phase 3(2)

Phase 1(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05843916Phase 3Completed

Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease

Role: lead

NCT05343715Phase 1Completed

PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion

Role: lead

NCT04036253Phase 3Completed

Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

Role: lead

NCT03822884Phase 1Completed

Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers

Role: lead

NCT01374373Phase 4Completed

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia

Role: lead

NCT01945788Phase 4Unknown

Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo

Role: lead

All 6 trials loaded